Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NBF-006 in Advanced Solid Tumors
NCT03819387Phase 1Completed
- Sponsor
- Nitto BioPharma, Inc.
- Start
- Mar 2019
- Primary completion
- Nov 2023
- Modality
- Lipid-based Nanoparticles, Conjugated siRNA, Chemically Modified siRNA
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nbf-006 in non-small cell lung cancer (NSCLC), pancreatic cancer (PC) and colorectal cancer (CRC), sponsored by Nitto BioPharma, Inc. Primary endpoint: Number of patients with treatment-related adverse events as assessed by CTCAE v5.0. Started Mar 2019; status: completed.
02
Drugs
nbf-006
03
Conditions
non-small cell lung cancer (NSCLC)pancreatic cancer (PC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03819387.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03819387.